=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:46:19 ON 24 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JAN 2005 HIGHEST RN 819046-01-0
DICTIONARY FILE UPDATES: 23 JAN 2005 HIGHEST RN 819046-01-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\ppgg.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:46:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2415 TO ITERATE

41.4% PROCESSED 1000 ITERATIONS 9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 45353 TO 51247
PROJECTED ANSWERS: 155 TO 713

L2 9 SEA SSS SAM L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	0.64

FILE 'CAPLUS' ENTERED AT 10:47:02 ON 24 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 24 Jan 2005 VOL 142 ISS 5
FILE LAST UPDATED: 23 Jan 2005 (20050123/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 10:48:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2415 TO ITERATE

41.4% PROCESSED 1000 ITERATIONS 9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 45353 TO 51247
PROJECTED ANSWERS: 155 TO 713

L3 9 SEA SSS SAM L1

L4 2 L3

=> d l4 ibib abs hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:473076 CAPLUS
DOCUMENT NUMBER: 133:252336
TITLE: Synthesis and Structure-Activity Relationships of 7-Substituted 3-(2,6-Dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as Selective Inhibitors of pp60c-src
AUTHOR(S): Thompson, Andrew M.; Rewcastle, Gordon W.; Boushelle, Stacey L.; Hartl, Brian G.; Kraker, Alan J.; Lu, Gina H.; Batley, Brian L.; Panek, Robert L.; Showalter, H. D. Hollis; Denny, William A.
CORPORATE SOURCE: Auckland Cancer Society Research Centre Faculty of Medical and Health Sciences, University of Auckland, Auckland, 92019, N. Z.
SOURCE: Journal of Medicinal Chemistry (2000), 43(16), 3134-3147
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 7-Substituted 3-(2,6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones are potent inhibitors of protein tyrosine kinases, with some selectivity for c-Src. The compds. were prepared by condensing 4,6-diaminonicotinaldehyde with 2,6-dichlorophenylacetonitrile and selectively converting the 2- and 7-amino groups of the product to hydroxy and fluoro groups, resp., by prolonged diazotization in 50% aqueous fluoroboric acid. N-Methylation, followed by treatment with aliphatic diamines, aromatic amines, or their derived lithium anions, gave the desired compds. Selected isomeric 1,8-naphthyridin-2(1H)-ones were also prepared in order to evaluate the relative contributions of both ring A aza atoms of the related pyrido[2,3-d]pyrimidin-7(8H)-ones to the inhibitory activity. The compds. were evaluated for their ability to prevent phosphorylation of a model substrate by c-Src, FGF-1 receptor, and PDGF-β receptor enzymes. Overall, there was a high degree of correlation of the activities against the different kinases, with c-Src being generally the most sensitive to

structural changes. 1,6-Naphthyridin-2(1H)-one analogs bearing basic aliphatic side chains [7-NH(CH2)nNRR, 7-NHC6H4O(CH2)nNRR, or 7-NHC6H4N(CH2)4NMe] were the most potent against c-Src (IC50s of 10-80 nM), showing good selectivity with respect to PDGFR (10-300-fold) but less with respect to FGFR. The 1,6-naphthyridin-2(1H)-ones showed broadly similar activity to the analogous pyrido[2,3-d]pyrimidin-7(8H)-ones, whereas the 1,8-naphthyridin-2(1H)-ones were at least 103-fold less potent. These results, indicating that the 3-aza atom in the pyrido[2,3-d]pyrimidin-7(8H)-ones is mandatory, whereas the 1-aza atom is not, support the published binding model for these compds. to c-Src (J. Med. Chemical 1998, 41, 1752), where the 3-aza and 2-NH atoms form a bidentate H-bond donor-acceptor motif that interacts with Met341 and the 1-aza atom is not involved in specific binding interactions.

IT **294659-62-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and structure-activity relationships of 7-substituted 3-(2,6-Dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60c-src)

RN 294659-62-4 CAPLUS
CN 1,6-Naphthyridin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[3-(diethylamino)propoxy]phenyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:139846 CAPLUS
DOCUMENT NUMBER: 130:196643
TITLE: Preparation of naphthyridinones as protein tyrosine kinase and cyclin dependant kinase inhibitors
INVENTOR(S): Barvian, Mark Robert; Denny, William Alexander; Dobrusin, Ellen Myra; Hamby, James Marino; Showalter, Howard Daniel Hollis; Thompson, Andrew Mark; Winters, Roy Thomas; Wu, Zhipei
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909030	A1	19990225	WO 1998-US16848	19980813

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9888289	A1	19990308	AU 1998-88289	19980813
AU 742999	B2	20020117		
EP 1003745	A1	20000531	EP 1998-939941	19980813
EP 1003745	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9811956	A	20000815	BR 1998-11956	19980813
JP 2001515078	T2	20010918	JP 2000-509710	19980813
NZ 502704	A	20020628	NZ 1998-502704	19980813
ZA 9807491	A	19990421	ZA 1998-7491	19980819
MX 9911792	A	20000630	MX 1999-11792	19991215
US 6150359	A	20001121	US 2000-463553	20000126
PRIORITY APPLN. INFO.:			US 1997-56746P	P 19970820
			WO 1998-US16848	W 19980813

OTHER SOURCE(S): MARPAT 130:196643

GI



I

AB Title compds. [I; R1 = halo or (un)substituted amino; R2 = (bi)(cyclo)alkyl; R5 = H, halo, (hetero)aryl, etc.; dashed line = optional bond] were prepared Thus, 4,6-diamino-3-pyridinecarboxaldehyde (preparation given) was cyclocondensed with 2,6-Cl2C6H3CH2CN and the major product treated with NaNO2/HBF4 to give, after N-methylation, major product I (R2 = Me, R5 = C6H3Cl2-2,6)(II; R1 = F) which was aminated to give II (R1 = e.g., NHMe). Data for biol. activity of I were given.

IT **220817-54-9P 220817-74-3P 220818-88-2P 220818-94-0P 220819-14-7P 220819-55-6P 220820-58-6P 220821-14-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthyridinones as protein tyrosine kinase and cyclin dependant kinase inhibitors)

RN 220817-54-9 CAPLUS

CN 1,6-Naphthyridin-2(1H)-one, 1-ethyl-7-[[4-(1H-tetrazol-5-yl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 220817-74-3 CAPLUS

CN 1,6-Naphthyridin-2(1H)-one, 1-ethyl-7-[[4-(1-pyrrolidinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 220818-88-2 CAPLUS
CN 1,6-Naphthyridin-2(1H)-one, 3-fluoro-1-methyl-7-[[4-(4-methyl-1-piperazinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 220818-94-0 CAPLUS
CN 1,6-Naphthyridin-2(1H)-one, 1-cycloheptyl-3-fluoro-7-[[4-(4-methyl-1-piperazinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 220819-14-7 CAPLUS
CN 1,6-Naphthyridin-2(1H)-one, 3-fluoro-1-methyl-7-[[4-(1H-pyrazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 220819-55-6 CAPLUS
CN 1,6-Naphthyridin-2(1H)-one, 3-fluoro-7-[[4-[3-(hydroxymethyl)-1-piperidinyl]phenyl]amino]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 220820-58-6 CAPLUS
CN 1,6-Naphthyridin-2(1H)-one, 3-(2,6-dichlorophenyl)-1-ethyl-7-[(4-fluoro-3-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 220821-14-7 CAPLUS
CN 1,6-Naphthyridin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT